Use of novel oral anticoagulants in patients with heart failure

Area of Science:

• Cardiology
• Thrombosis
• Pharmacology

Background:

• Heart failure (HF) is associated with a prothrombotic state, particularly in the atria when complicated by atrial fibrillation (AF).
• Dilated, dysfunctional cardiac chambers, as seen in myocardial infarction or cardiomyopathy, predispose patients to thrombogenesis.
• Existing research on novel oral anticoagulants (NOACs) in AF patients with HF is based on subgroup analyses.

Purpose of the Study:

• To evaluate the efficacy and safety of NOACs in AF patients with concomitant heart failure.
• To identify knowledge gaps regarding NOAC use in specific heart failure populations.

Main Methods:

• Subgroup analyses of phase 3 randomized trials involving patients with AF and HF.
• Comparison of NOACs' effectiveness and safety in patients with HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF).

Main Results:

• NOACs demonstrated equal effectiveness and safety in AF patients with HF compared to those without HF.
• This finding applies to both HFrEF and HFpEF, although HFpEF patients with LVEF ≥ 55% were not specifically analyzed.
• No clinical trial data exists on NOAC utility in HF patients in sinus rhythm.

Conclusions:

• NOACs are a viable therapeutic option for AF patients with HF.
• Further research is needed to clarify NOAC efficacy and safety in HF patients in sinus rhythm and specific HFpEF subgroups.
• Current evidence supports NOAC use across different HF phenotypes in AF patients, but broader patient populations require investigation.